F
Fabrizio Vianello
Researcher at University of Padua
Publications - 105
Citations - 2776
Fabrizio Vianello is an academic researcher from University of Padua. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 21, co-authored 93 publications receiving 2343 citations. Previous affiliations of Fabrizio Vianello include Harvard University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang,Jianping Yuan,Elda Righi,Walid S. Kamoun,Marek Ancukiewicz,Jean Nezivar,Michael Santosuosso,John D. Martin,Margaret R. Martin,Fabrizio Vianello,Pierre Leblanc,Lance L. Munn,Peigen Huang,Dan G. Duda,Dai Fukumura,Rakesh K. Jain,Mark C. Poznansky +16 more
TL;DR: It is demonstrated that targeting tumor vasculature with lower vascular-normalizing doses, but not high antivascular/antiangiogenic doses, of an anti-VEGF receptor 2 (VEGFR2) antibody results in a more homogeneous distribution of functional tumor vessels.
Journal ArticleDOI
CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer
Elda Righi,Satoshi Kashiwagi,Jianping Yuan,Michael Santosuosso,Pierre Leblanc,Rachel Ingraham,Benjamin Forbes,Beth Edelblute,Brian Collette,Deyin Xing,Magdalena Kowalski,Magdalena Kowalski,Maria Cristina Mingari,Fabrizio Vianello,Michael J. Birrer,Sandra Orsulic,Sandra Orsulic,Glenn Dranoff,Mark C. Poznansky +18 more
TL;DR: Modulation of the CXCL12/CXCR4 axis in ovarian cancer has multimodal effects on tumor pathogenesis associated with induction of antitumor immunity and offers a definitive preclinical validation of CX CR4 as a therapeutic target in this disease.
Journal ArticleDOI
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis
Fabrizio Vianello,Federica Villanova,Veronica Tisato,Stefania Lymperi,Ka Kei Ho,Ana R. Gomes,David Marin,Dominique Bonnet,Jane F. Apperley,Eric Lam,Francesco Dazzi +10 more
TL;DR: Human mesenchymal stromal cells mediate protection of chronic myeloid leukemia cells from imatinib-induced apoptosis and the combination of anti-CXCR4 antagonists with tyrosine kinase inhibitors may represent a powerful approach to the treatment of chronicMyeloids leukemia.
Journal ArticleDOI
MYH9-related disease: A novel prognostic model to predict the clinical evolution of the disease based on genotype-phenotype correlations
Alessandro Pecci,Catherine Klersy,Paolo Gresele,Kieran J.D. Lee,Daniela De Rocco,Valeria Bozzi,Giovanna Russo,Paula G. Heller,Giuseppe Loffredo,Matthias Ballmaier,Fabrizio Fabris,Eloise Beggiato,Walter H. A. Kahr,Nuria Pujol-Moix,Helen Platokouki,Christel Van Geet,Patrizia Noris,Preethi Yerram,Cédric Hermans,Bernhard Gerber,Marina Economou,Marco R. de Groot,Barbara Zieger,Erica De Candia,Vincenzo Fraticelli,Rogier Kersseboom,Giorgina Barbara Piccoli,Stefanie Zimmermann,Tiziana Fierro,Ana C. Glembotsky,Fabrizio Vianello,Carlo Zaninetti,Elena Nicchia,Christiane Guthner,Carlo Baronci,Marco Seri,Peter J. Knight,Carlo L. Balduini,Anna Savoia +38 more
TL;DR: Findings in genotype–phenotype correlations are essential to patients' clinical management and genetic counseling and are discussed in view of molecular pathogenesis of MYH9‐RD.
Journal ArticleDOI
Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control
Fabrizio Vianello,Natalia Papeta,Tao Chen,Paul Kraft,Natasha D. White,William K. Hart,Moritz F. Kircher,Eric F. Swart,Sarah Rhee,Giorgio Palù,Daniel Irimia,Mehmet Toner,Ralph Weissleder,Mark C. Poznansky +13 more
TL;DR: The repulsion of tumor Ag-specific T cells away from melanomas expressing CXCL12 confirms the chemorepellent activity of high concentrations of CXCl12 and may represent a novel mechanism by which certain tumors evade the immune system.